NCT00565331View on ClinicalTrials.gov

Rituximab for Prevention of Rejection After Renal Transplantation

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

280

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

December 31, 2013

Study Completion Date

June 30, 2015

Conditions

Kidney Transplantation

Interventions

DRUG

Rituximab

single dose of rituximab of 375 mg/m2 intravenously at the time of transplantation

DRUG

Placebo

saline solution

Trial Locations (1)

6500 HB

Radboud University Nijmegen Medical Centre, Nijmegen

Sponsors

Collaborators (1)

Astellas Pharma GmbH

All Listed Sponsors

collaborator

Hoffmann-La Roche

INDUSTRY

collaborator

Astellas Pharma GmbH

INDUSTRY

lead

Radboud University Medical Center

OTHER

NCT00565331 - Rituximab for Prevention of Rejection After Renal Transplantation | Biotech Hunter | Biotech Hunter